Tianshu Pharmaceutical Selected into the Third Batch of Special Projects for Provincial High-Quality Manufacturing Development in 2023

Recently, the Hubei Provincial Department of Economy and Information Technology announced the third batch of special projects for provincial high-quality manufacturing development in 2023, and Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was successfully selected into the list.

The special project for provincial high-quality manufacturing development, initiated by the Hubei Provincial Department of Economy and Information Technology, focuses on the five breakthrough development advantage industries and nine emerging characteristic industries identified by the Provincial Party Committee and Provincial Government. It aims to promote industrial upgrading and technological improvement of enterprises in the province, with key support for the construction of projects that meet requirements such as enhancing industrial innovation capabilities and accelerating industrial integration and development.

Since its establishment, Tianshu Pharmaceutical has adhered to a differentiated development path, with the goal of promoting high-quality development. It has focused on innovative drug CDMO services, as well as the R&D, production and sales of high-end APIs and advanced pharmaceutical intermediates. Centering on product pipelines such as contrast agents, cardiovascular and cerebrovascular drugs, oncology drugs, and autoimmune drugs, it has continuously optimized industrial strategic layout and technological upgrading, made continuous breakthroughs and innovations, and further strengthened the construction of innovation capabilities and core competitiveness, which is highly in line with the support policies for the provincial high-quality manufacturing development special project. Following the strategic deployment of its parent company Vcare PharmaTech, Tianshu Pharmaceutical has built its innovation and production capabilities, and achieved remarkable results in intelligent production.

The approval and establishment of this project has accelerated the construction of Tianshu Pharmaceutical's R&D and production capabilities, further promoted its technological progress and capability improvement in high-end API and CDMO intelligent production, and laid a foundation for the company's high-quality development.